Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation
| Status: | Not yet recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 11/29/2018 |
| Start Date: | April 2019 |
| End Date: | December 2023 |
| Contact: | Donald J. Hagler, M.D. |
| Email: | hagler@mayo.edu |
| Phone: | 507-255-6670 |
PFOCUS Pilot Trial- A Prospective Pilot Trial for PFO ClosUre at the Time of endovaScular Cardiac Electronic Device Implantation
Participants enrolled in this study will have been diagnosed with patent foramen ovale (PFO)
and have been scheduled to have a cardiovascular implantable electronic device (CIED) such as
a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization
therapy (CRT) device implanted. A PFO is a condition when there is a hole in the septum (the
wall separating the right and left sides) of the heart.
The purpose of this study is to determine whether closing the PFO with the GORE® Cardioform
Septal Occluder in people with an endocardial device leads reduces the risk of recurrent
stroke or imaging-confirmed transient ischemic attack (TIA) compared to not closing the PFO.
and have been scheduled to have a cardiovascular implantable electronic device (CIED) such as
a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization
therapy (CRT) device implanted. A PFO is a condition when there is a hole in the septum (the
wall separating the right and left sides) of the heart.
The purpose of this study is to determine whether closing the PFO with the GORE® Cardioform
Septal Occluder in people with an endocardial device leads reduces the risk of recurrent
stroke or imaging-confirmed transient ischemic attack (TIA) compared to not closing the PFO.
Inclusion Criteria:
- A clinical indication for a transvenous pacemaker or defibrillator implantation,
- Must have a documented PFO determined from Transthoracic Echocardiogram (TTE)
echocardiographic agitated saline contrast study that is determined to be feasible for
transcatheter closure.
- The GORE® CARDIOFORM Septal Occluder should only be used in subjects whose vasculature
is adequate to accommodate a 10 Fr delivery sheath (or 12 Fr delivery sheath when a
guidewire is used).
- All subjects must be able to undergo standardized neurocognitive testing, and
dementia/mental status examination screening.
Exclusion Criteria:
- Subjects with a survival expectancy of less than one year.
- Subjects with an atrial septal defect or shunt that clinically requires closure for
hemodynamic or other purposes.
- Absence of a clinical indication for a transvenous CIED system.
- Subjects with any clinical indication mandating anticoagulation.
- Subjects with previously placed CIED devices will be excluded.
- Unable to take anti-platelet medications such as aspirin or clopidogrel (Plavix).
- With anatomy where the GORE® CARDIOFORM Septal Occluder size or position would
interfere with other intracardiac or intravascular structures, such as cardiac valves
or pulmonary veins.
- With active endocarditis, or other infections producing bacteremia, or with known
sepsis within one month of planned implantation, or any other infection that cannot be
treated successfully prior to device placement.
- With known intracardiac thrombi.
- Known pregnancy at the time of automated implantable cardioverter-defibrillator (AICD)
implant
We found this trial at
1
site
200 First Street SW
Rochester, Minnesota 55905
Rochester, Minnesota 55905
507-284-2511
Phone: 507-255-6670
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
